Semaglutide for Opioid Use Disorder: $13.3M Trial Planned in Allegheny County
October 15, 2026
A $13.3 million trial of semaglutide for opioid use disorder is being prepared in Allegheny County, Pennsylvania. The Center for Addiction Science, Policy and Research (CASPR) and the county’s Department of Human Services plan to enroll up to 1,200 adults with alcohol or opioid use disorder, with the study expected to launch in early 2027.
How the semaglutide for opioid use disorder study works
Half of the participants will take semaglutide weekly for 52 weeks. It is added to standard treatment, not offered in place of it. The grant comes from Arnold Ventures, and UPMC Western Psychiatric Hospital’s Addiction Medicine Services will serve as the lead clinical site.
The study will also use Allegheny County’s linked administrative data to track employment, housing, health care use and contact with the justice system, not only substance use. For background on another treatment option, read our piece on buprenorphine and telehealth.
Why it matters
Semaglutide is already approved for type 2 diabetes and weight management, and early studies suggest it reduces drinking and opioid cravings. Most addiction drug trials measure only substance use, so this design asks a wider question: whether treatment changes a person’s stability and the cost to public systems. Because the intervention is a medicine given through existing care, a positive result could be more straightforward for other health systems and counties to adopt. Safety will matter as much as benefit, and our report on the rise in semaglutide adverse reactions in Sweden shows why.
Let Google know we are your trusted source.
Add our editorial as a preferred source in your search results.
Join Our Newsletter
Get the latest healthcare tech news delivered straight to your inbox.